Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies

Medical Mycology

Volumn 50, Issue 5, 2012, Pages 543-548

  Cahuayme Zuniga, Lizbeth ^a   Lewis, Russell E ^a,b   Mulanovich, Victor E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Invasive fungal infection; Liposomal amphotericin B; Secondary prophylaxis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CLOFARABINE; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; FLUCONAZOLE; IDARUBICIN; ITRACONAZOLE; POSACONAZOLE; TACROLIMUS; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FUSARIOSIS; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG MYCOSIS; MALE; MANTLE CELL LYMPHOMA; MUCORMYCOSIS; NEUTROPENIA; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AMPHOTERICIN B; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYCOSES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862198790     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.631152     Document Type: Review

References (28)

1. Person AK, Kontoyiannis DP, Alexander DP. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010; 24 : 439-459.
2. De la Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogenic blood and marrow transplant recipients. Transpl Infect Dis 2002; 4 : 2-9.
3. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the effi cacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42 : 1584-1591.
4. Vehreschild JJ, Sieniawski M, Reuter S, e t al . Effi cacy of caspofungin and itraconazole as secondary antifungal prophylaxis: Analysis of data from a multinational case registry. Int J Antimicrob Agents 2009; 34 : 446-450.
5. El-Cheikh J, Faucher C, Furst S, et al . High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39 : 301-306. (Pubitemid 46322637)
6. Perfect JR, Klotman ME, Gilbert CC, e t al . Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165 : 891-897.
7. Bodey GP, Anaissie EJ, Elting LS, et al . Antifungal prophylaxis during remission induction therapy for acute leukemia fl uconazole versus intravenous amphotericin B. Cancer 1994; 73 : 2009.
8. Wolff SN, Fay J, Stevens D, et al . Fluconazole vs. low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25 : 853-859. (Pubitemid 30209678)
9. Cordonnier C, Mohty M, Faucher C, e t al . Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31 : 135-141.
10. Tollemar J, Ringden O, Andersson S, e t al . Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12 : 577-582. (Pubitemid 24020989)
11. Kelsey SM, Goldman JM, McCann S, e t al . Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23 : 163-168. (Pubitemid 29048218)
12. Gubbins PO, Amsden JR, McConell SA, Anaissie EJ. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or a daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother 2009; 53 : 3664-3674.
13. De Pauw B, Walsh TJ, Donnelly JP, e t al . Revised defi nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). Clin Infect Dis 2008; 46 : 1813-1821.
14. Bellomo R, Ronco C, Kellum JA, e t al . Acute renal failure defi nition, outcome measures, animal models, fl uid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8 : R204-212.
15. Segal BH, Herbrecht R, Stevens DA, e t al . Defi ning responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis 2008; 47 : 674-683.
16. Segal BH, Almyroudis NG, Battiwalla M, e t al . Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplants recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44 : 402-409. (Pubitemid 46147624)
17. Mele L, Pagano L, Equitani F, Leona G. Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment with haematological malignancy. Mycoses 2001; 44 : 201-203. (Pubitemid 32641513)
18. Sevilla J, Hernandez-Maraver D, Aquado MJ, et al . Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis. Ann Hematol 2001; 80 : 456-459. (Pubitemid 32771607)
19. Nosari A, Oreste P, Cairoli R, e t al . Invasive aspergillosis in haematological malignancies: clinical fi ndings and management for intensive chemotherapy completion. Am J Hematol 2001; 68 : 231-236. (Pubitemid 33108425)
20. Tedeshi A, Montillo M, Cairoli M, et al . Prior invasive pulmonary and cerebellar mucormycosis is not a primary contraindication to perform an autologous stem cell transplantation in leukemia. Leuk Lymphoma 2002; 43 : 657-659. (Pubitemid 34232940)
21. Cordonnier C, Maury S, Pautas S, et al . Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33 : 943-948. (Pubitemid 38660128)
22. Kruger WH, R ü ssmann B, de Wit M, et al . Haemopoietic cell transplantation of patients with history with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematologica 2005; 113 : 104-108. (Pubitemid 40522813)
23. Vaidya SJ, Ortin M, Loperz-Duarte M, et al . Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection. Leuk Lymphoma 2005; 46 : 1143-1150. (Pubitemid 41087018)
24. Nosari A, Ravini M, Cairoli R, e t al . Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007; 39 : 631-635. (Pubitemid 46722843)
25. De Fabritis P, Spagnoli A, Di Bartolomeo P, e t al . Effi cacy of caspofungin as secondary prophylaxis in patients undergoing allogenic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40 : 245-249. (Pubitemid 47108468)
26. Cornely OA, Bohme A, Reichert A, e t al . Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61 : 939-946. (Pubitemid 351426082)
27. Zhang P, Song A, Wang S, e t al . Hematopoietic SCT in patients with history of invasive fungal infection. Bone Marrow Transplant 2009; 43 : 533-537.
28. Cordonnier C, Rovira M, Maertens J, et al . Voriconazole for secondary prophylaxis of invasive fungal infections in allogenic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95 : 1762-1768.